Compugen Ltd. (NASDAQ:CGEN) Q4 2023 Earnings Conference Call March 5, 2024 8:30 AM ET

Company Participants

Yvonne Naughton - Head of Investor Relations and Corporate Communications

Anat Cohen-Dayag - President and Chief Executive Officer

Alberto Sessa - Chief Financial Officer

Eran Ophir - Chief Scientific Officer

Michelle Mahler - Chief Medical Officer

Conference Call Participants

Asthika Goonewardene - Truist Securities

Daina Graybosch - Leerink Partners

Stephen Willey - Stifel

Operator

Ladies and gentlemen, thank you for joining us today. Welcome to Compugen's Fourth Quarter and Full Year 2023 Results Conference Call. At this time, all participants are in a listen-only mode. An audio webcast of this call is available in the Investors section of Compugen's website www.cgen.com. As a reminder, today's call is being recorded.

I would now like to introduce Yvonne Naughton, Head of Investor Relations and Corporate Communication. Yvonne, please go ahead.

Yvonne Naughton

Thank you, operator, and thank you all for joining us on the call today. Joining me from Compugen for the prepared remarks are Dr. Anat Cohen-Dayag, President and Chief Executive Officer; and Alberto Sessa, Chief Financial Officer; Dr. Michelle Mahler, Chief Medical Officer; and Dr. Eran Ophir, Chief Scientific Officer, will join us for the Q&A.

Before we begin, we would like to remind you that during this call, the company may make projections or forward-looking statements regarding future events, business outlook, development efforts and the potential outcome, the company's discovery platform, anticipated progress and plans, results and time lines for our programs, financial and accounting related matters as well as statements regarding our cash position.

We wish to caution you that such statements reflect only the company's current beliefs, expectations and assumptions, but actual results, performance or achievements of the company may differ materially.

These statements are subject to known and unknown risks and uncertainties, and we refer you to the SEC filings for more details on these risks, including in the company's most recent annual report on Form 20-F. The company undertakes no obligation to update projections and forward-looking statements in the future.

And with that, I'll turn the call over to Anat.

Anat Cohen-Dayag

Thank you, Yvonne, and thanks to everyone for joining our call today. Before we discuss the full year and fourth quarter highlights, I want to start by welcoming the new addition to our management team, Michelle Mahler, who took over the role of Chief Medical Officer on March 1st, 2024.